2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 26-32. PMID: 33145460, PMCID: PMC7598436, DOI: 10.1016/j.adro.2020.10.003.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultationsProstate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 659-665. PMID: 32292839, PMCID: PMC7118610, DOI: 10.1016/j.adro.2020.03.010.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultations
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparities